Depressive and anxiety symptomatology in ecstasy users: The relative contribution of genes, trauma, life stress and drug use

Psychopharmacology

Volumn 209, Issue 1, 2010, Pages 25-36

  Scott, Rebecca M ^a   Hides, Leanne ^b   Allen, J Sabura ^a   Burke, Richard ^a   Lubman, Dan I ^b  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Anxiety; Depression; Ecstasy; Life stress; MDMA; Risk factors; Serotonin transporter; Trauma

Indexed keywords

GENOMIC DNA; SEROTONIN TRANSPORTER;

ADULT; ANXIETY; ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DNA POLYMORPHISM; DRUG USE; ENVIRONMENTAL FACTOR; GENE; HEREDITY; HUMAN; INJURY; LIFE STRESS; MAJOR CLINICAL STUDY; MULTIPLE DRUG ABUSE; PRIORITY JOURNAL; QUESTIONNAIRE; RISK FACTOR; SMOKING CESSATION; SYMPTOMATOLOGY;

ADOLESCENT; ADULT; AFFECT; ANXIETY; DEPRESSION; FEMALE; HALLUCINOGENS; HUMANS; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; POLYMORPHISM, GENETIC; QUESTIONNAIRES; RISK FACTORS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; STRESS, PSYCHOLOGICAL; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 77649235869     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-009-1763-5     Document Type: Article

References (58)

1. AB Abdallah LM Scheier JA Inciardi J Copeland LB Cottler 2007 A psycho-economic model of ecstasy consumption and related consequences: a multisite study with community samples Subst Use Misuse 42 1651 1684 10.1080/10826080701208905 17934989 (Pubitemid 47575082)
2. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders DSM-IV-TR, 4th edn. American Psychiatric Association, Arlington
3. M Anglin Y-I Hser C-P Chou 1993 Reliability and validity of retrospective behavioral self-report by narcotics addicts Eval Rev 17 91 108 10.1177/0193841X9301700107
4. Australian Bureau of Statistics (2007) National survey of mental health and wellbeing: summary of results, 2007. Available via http://www.ausstats.abs. gov.au/ausstats/subscriber.nsf/0/6AE6DA447F985F2CA2574EA00122BD6/$File/ 43260-2007.pdf. Accessed 5 Aug 2009
5. Australian Institute of Health and Welfare (2008) 2007 National drug strategy household survey: detailed findings. Available via http://www.aihw.gov. au/publications/phe/ndshs07-df/ndshs07-df.pdf. Accessed 4 Aug 2009
6. G Bedi J Redman 2006 Self-reported ecstasy use: the impact of assessment method on dosage estimates in recreational users J Psychopharmacol 20 432 436 10.1177/0269881106063272 16574718
7. G Bedi NT Van Dam J Redman 2008 Ecstasy (MDMA) and high prevalence symptomatology: somatic anxiety symptoms are associated with polydrug, not ecstasy, use J Psychopharmacol 0 1 8
8. JA Buckby AR Yung EM Cosgrave EJ Killackey 2007 Clinical utility of the Mood and Anxiety Symptom Questionnaire (MASQ) in a sample of young help-seekers BMC Psychiatry 7 50 10.1186/1471-244X-7-50 10.1186/1471-244X-7-50 17868477
9. DP Chapman CL Whitfield VJ Felitti SR Dube VJ Edwards RF Anda 2004 Adverse childhood experiences and the risk of depressive disorders in adulthood J Affect Disord 82 217 225 10.1016/j.jad.2003.12.013 15488250 (Pubitemid 39370823)
10. RS Cohen 1995 Subjective reports on the effects of the MDMA ('ecstasy') experience in humans Prog Neuro-Psychopharmacol Biol Psychiatry 19 1137 1145 10.1016/0278-5846(95)00231-6 1:CAS:528:DyaK28XmvFSrsg%3D%3D (Pubitemid 26016856)
11. J Cole H Sumnall C Grob 2002 Sorted: ecstasy facts from fiction Psychologist 15 464 467
12. WE Copeland G Keeler A Angold J Costello 2007 Traumatic events and posttraumatic stress in childhood Arch Gen Psychiatry 64 577 584 10.1001/archpsyc.64.5.577 17485609 (Pubitemid 46718290)
13. M Creamer P Burgess AC McFarlane 2001 Post-traumatic stress disorder: findings from the Australian National Survey of Mental Health and well-being Psychol Med 31 1237 1247 10.1017/S0033291701004287 1:STN:280: DC%2BD3MrntlGmug%3D%3D 11681550 (Pubitemid 32975889)
14. HV Curran 2000 Is MDMA ('ecstasy') neurotoxic in humans? An overview of evidence and of methodological problems in research Neuropsychobiology 42 34 41 10.1159/000026668 1:CAS:528:DC%2BD3cXlvVems7o%3D 10867554
15. J Daumann G Hensen B Thimm M Rezk B Till E Gouzoulis-Mayfrank 2004 Self-reported psychopathological symptoms in recreational ecstasy (MDMA) users are mainly associated with regular cannabis use: further evidence from a combined cross-sectional/longitudinal investigation Psychopharmacol 173 398 404 10.1007/s00213-003-1719-0 1:CAS:528:DC%2BD2cXjslOrs78%3D (Pubitemid 38703814)
16. R De Graaf RV Bijl F Smit WAM Vollebergh J Spijker 2002 Risk factors for 12 month comorbidity of mood, anxiety and substance use disorders: findings from The Netherlands Mental Health Survey and Incidence Study Am J Psychiatry 159 620 629 10.1176/appi.ajp.159.4.620 11925301 (Pubitemid 34274945)
17. F Del Boca J Darkes 2003 The validity of self-reports of alcohol consumption: state of the science and challenges for research Addiction 98 1 12 10.1046/j.1359-6357.2003.00586.x 14984237
18. BS Dohrenwend L Krasnoff AR Askenasy BP Dohrenwend 1978 Exemplification of a method for scaling life events: the PERI Life Events Scale J Health Soc Behav 19 205 229 10.2307/2136536 1:STN:280:DyaE1c3ktlWqsw%3D%3D 681735
19. W Fals-Stewart TJ O'Farrell TT Freitas SK McFarlin P Rutigliano 2000 The timeline followback reports of psychoactive substance use by drug-abusing patients: psychometric properties J Consult Clin Psychol 68 134 144 10.1037/0022-006X.68.1.134 1:STN:280:DC%2BD3c7ns1WrsQ%3D%3D 10710848
20. DM Fergusson MT Lynskey 1997 Physical punishment/maltreatment during childhood and adjustment in young adulthood Child Abuse Negl 21 617 630 10.1016/S0145-2134(97)00021-5 1:STN:280:DyaK2szotFWruw%3D%3D 9238545 (Pubitemid 27287225)
21. RA Furlong L Ho C Walsh JS Rubinsztein S Jain ES Paykel, et al. 1998 Analysis and meta-analysis of two serotonin transporter gene polymorphisms in bipolar and unipolar affective disorders Am J Med Genet B Neuropsychiatr Genet 81 58 63 10.1002/(SICI)1096-8628(19980207)81:1<58::AID-AJMG11>3.0.CO;2-V 1:STN:280:DyaK1c7ntlGhtw%3D%3D (Pubitemid 28114852)
22. D Goldberg 1994 A bio-social model for common mental disorders Acta Psychiatr Scand 90 66 70 10.1111/j.1600-0447.1994.tb05916.x
23. A Heils A Teufel S Petri G Stober P Riederer D Bengel, et al. 1996 Allelic variation of human serotonin transporter gene expression J Neurochem 66 2621 2624 1:CAS:528:DyaK28XjtFCrsrk%3D 8632190
24. KS Kendler CO Gardner CA Prescott 2002 Towards a comprehensive developmental model for major depression in women Am J Psychiatry 159 1133 1145 10.1176/appi.ajp.159.7.1133 12091191 (Pubitemid 34743253)
25. KS Kendler CO Gardner CA Prescott 2006 Towards a comprehensive developmental model for major depression in men Am J Psychiatry 163 115 124 10.1176/appi.ajp.163.1.115 16390898 (Pubitemid 43050112)
26. KS Kessler 1997 The effects of stressful life events on depression Annu Rev Psychol 48 191 214 10.1146/annurev.psych.48.1.191 1:STN:280: DyaK2s7pvVGitA%3D%3D 9046559
27. EM Kouri HG Pope Jr 2000 Abstinence symptoms during withdrawal from chronic marijuana use Exp Clin Psychopharmacol 8 483 492 10.1037/1064-1297.8.4. 483 1:CAS:528:DC%2BD3cXovF2ksrc%3D 11127420
28. CTJ Lamers A Bechara M Rizzo JG Raemakers 2006 Cognitive function and mood in MDMA/THC users, THC users and non-drug using controls J Psychopharmacol 20 302 311 10.1177/0269881106059495 1:STN:280:DC%2BD287isVehtg%3D%3D 16510488
29. KP Lesch D Bengel A Heils SZ Sabol BD Greenberg S Petri, et al. 1996 Association of anxiety related traits with a polymorphism in the serotonin transporter gene regulatory region Science 274 1527 1531 10.1126/science.274. 5292.1527 1:CAS:528:DyaK28Xnt1ansL8%3D 8929413 (Pubitemid 26403928)
30. DI Lubman NB Allen N Rogers E Cementon Y Bonomo 2007 The impact of co-occurring mood and anxiety disorders among substance-abusing youth J Affect Disord 103 105 112 10.1016/j.jad.2007.01.011 17291589 (Pubitemid 47445759)
31. N MacInnes SL Handley GFA Harding 2001 Former chronic methylenedioxymethamphetamine (MDMA or ecstasy) users report mild depressive symptoms J Psychopharmacol 15 181 186 10.1177/026988110101500310 1:CAS:528:DC%2BD3MXnt1Sms70%3D 11565625
32. UD McCann Z Szab M Vranesic M Palermo WB Mathews HT Ravert, et al. 2008 Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (±)3, 4 methylenedioxymethamphetamine ("ecstasy") users: relationship to cognitive performance Psychopharmacol 200 439 450 10.1007/s00213-008-1218-4 1:CAS:528: DC%2BD1cXhtFOjsbzK
33. K McCardle S Luebbers JD Carter RJ Croft C Stough 2004 Chronic MDMA (ecstasy) use, cognition and mood Psychopharmacol 173 434 439 10.1007/s00213-004-1791-0 1:CAS:528:DC%2BD2cXjslOrsb8%3D (Pubitemid 38703819)
34. J McCauley DE Kern K Kolodner L Dill AF Schroeder HK DeChant, et al. 1997 Clinical characteristics of women with a history of childhood abuse: unhealed wounds J Am Med Assoc 277 1362 1368 10.1001/jama.277.17.1362 1:STN:280:DyaK2s3otVKitg%3D%3D
35. KL Medina PK Shear 2007 Anxiety, depression, and behavioural symptoms of executive dysfunction in ecstasy users: contributions of polydrug use Drug Alcohol Depend 87 303 311 10.1016/j.drugalcdep.2006.09.003 17074449 (Pubitemid 46215937)
36. HG Pope Jr AJ Gruber JI Hudson MA Huestis D Yurgelun-Todd 2001 Neuropsychological performance in long-term cannabis users Arch Gen Psychiatry 58 909 915 10.1001/archpsyc.58.10.909 11576028
37. Quinn C, Dunn M, Degenhardt L (2007) The illicit tablet market in Victoria, 2004-2007. EDRS drug trends bulletin, December 2007. National Drug and Alcohol Research Centre, University of New South Wales, Sydney
38. GA Ricaurte J Yuan UD McCann 2000 (±)3, 4- Methylenedioxymethamphetamine ('ecstasy')-induced serotonin neurotoxicity: studies in animals Neuropsychobiology 42 5 10 10.1159/000026664 1:CAS:528:DC%2BD3cXlvVemsrk%3D 10867550
39. N Risch R Herrell T Lehner K-Y Liang L Eaves J Hoh, et al. 2009 Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta analysis J Am Med Assoc 301 2462 2471 10.1001/jama.2009.878 1:CAS:528:DC%2BD1MXnsFWgurc%3D
40. JP Roiser BJ Sahakian 2004 Relationship between ecstasy use and depression: a study controlling for poly-drug use Psychopharmacol 173 411 417 10.1007/s00213-003-1705-6 1:CAS:528:DC%2BD2cXjslOrsrg%3D (Pubitemid 38703816)
41. JP Roiser LJ Cook JD Cooper DC Rubinsztein BJ Sahakian 2005 Association of a functional polymorphism in the serotonin transporter gene with abnormal emotional processing in ecstasy users Am J Psychiatry 162 609 612 10.1176/appi.ajp.162.3.609 15741482 (Pubitemid 40343932)
42. PK Schraedley RJ Turner IH Gotlib 2002 Stability of retrospective reports in depression: traumatic events, past depressive episodes, and parental psychopathology J Health Soc Behav 43 307 316 10.2307/3090206 12467255
43. LB Shillington DE Cottler WM Mager I Compton 1995 Self-report stability for substance use over 10 years: data from the St. Louis Epidemiologic Catchment Study Drug Alcohol Depend 40 103 109 10.1016/0376-8716(95)01176-5 1:STN:280:DyaK28zkvVGisA%3D%3D 8745131 (Pubitemid 26011972)
44. TL Simpson WR Miller 2002 Concomitance between childhood sexual and physical abuse. A review Clin Psychol Rev 22 27 77 10.1016/S0272-7358(00)00088-X 11793578 (Pubitemid 33109012)
45. LT Singer TJ Linares S Ntiri R Henry S Minnes 2004 Psychosocial profiles of older adolescent MDMA users Drug Alcohol Depend 74 245 252 10.1016/j.drugalcdep.2003.12.015 15194202 (Pubitemid 38759779)
46. Sobell LC, Sobell MB (1992) Timeline followback: a technique for assessing self reported alcohol consumption. In: Allen RLJ (ed) Measuring alcohol consumption: psychosocial and biological methods. Humana, Totowa, pp 159-172
47. N Solowij W Hall N Lee 1992 Recreational MDMA use in Sydney: a profile of 'ecstasy' users and their experiences with the drug Br J Addict 87 1161 1172 10.1111/j.1360-0443.1992.tb02003.x 1:STN:280:DyaK38znvFCiug%3D%3D 1354992
48. PK Staiger F Melville L Hides N Kambouropoulos DI Lubman 2009 Can emotion-focused coping help explain the link between posttraumatic stress disorder severity and triggers for substance use in young adults? J Subst Abuse Treat 36 220 226 10.1016/j.jsat.2008.05.008 18657937
49. HR Sumnall JC Cole 2005 Self-reported depressive symptomatology in community samples of polysubstance misusers who report ecstasy use: a meta-analysis J Psychopharmacol 19 84 92 10.1177/0269881105048901 15671133
50. HR Sumnall GF Wagstaff JC Cole 2004 Self-reported psychopathology in polydrug users J Psychopharmacol 18 75 82 10.1177/0269881104040239 15107188 (Pubitemid 38623097)
51. L Topp J Hando P Dillon A Roche N Solowij 1999 Ecstasy use in Australia: patterns of use and associated harm Drug Alcohol Depend 55 105 115 10.1016/S0376-8716(99)00002-2 1:STN:280:DyaK1MzivVKjtw%3D%3D 10402155 (Pubitemid 29222009)
52. United Nations Office on Drugs and Crime (2008) 2008 World drug report. Available via http://www.unodc.org/documents/wdr/WDR-2008/WDR-2008-eng-web.pdf. Accessed 4 Aug 2009
53. United Nations Office on Drugs and Crime (2009) 2009 World drug report. United Nations, New York
54. SL Verheyden R Maidment HV Curran 2003 Quitting ecstasy: an investigation of why people stop taking the drug and their subsequent mental health J Psychopharmacol 17 371 378 10.1177/0269881103174014 1:CAS:528: DC%2BD2cXhs1Kit70%3D 14870948 (Pubitemid 38076331)
55. Watson D, Clark LA (1991) The mood and anxiety symptom questionnaire. University of Iowa, Iowa City
56. D Watson K Weber JS Assenheimer LA Clark ME Strauss RA McCormick 1995 Testing a tripartite model: I. Evaluating the convergent and discriminant validity of anxiety and depression symptom scales J Abnorm Psychol 104 3 14 10.1037/0021-843X.104.1.3 1:STN:280:DyaK2M3gsVOnsw%3D%3D 7897050
57. B White L Degenhardt C Breen R Bruno J Newman P Proudfoot 2006 Risk and benefit perceptions of party drug use Addict Behav 31 137 142 10.1016/j.addbeh.2005.04.003 15907371 (Pubitemid 41790456)
58. World Health Organisation (1997) Composite International Diagnostic Interview: version 2.1. World Health Organisation, Geneva